Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Samy Suissa, Sophie Dell'Aniello, Pierre Ernst. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 Year: 2017 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 The impact of preventive treatment with long-acting β2 adrenergics agonists and inhaled glucocorticoids in the morbility and mortality of 1.543 events of severe acute exacerbations of asthma Source: Annual Congress 2009 - Epidemiology of atopy and asthma Year: 2009 Combination therapy of inhaled corticosteroids and long-acting beta2-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking Source: Eur Respir J 2006; 28: Suppl. 50, 454s Year: 2006 Excess morbidity and mortality in patients with asthma on long-acting beta2-agonists Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths Year: 2007 Impact of inhaled corticosteroids in patients with cardiovascular disease Source: Eur Respir Monogr 2020; 88: 251-263 Year: 2020 Risks of diabetes mellitus and hyperglycaemic adverse events in patients with COPD taking inhaled corticosteroids Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics Source: Eur Respir J 2001; 17: 380-385 Year: 2001 Adherence to inhaled controller therapy and local adverse events in children with asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Cardiovascular safety of high doses of the nebulized bronchodilators in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Source: Eur Respir J 2010; 35: 1003-1021 Year: 2010 Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018 Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002 Risks of diabetes mellitus and hyperglycaemic adverse events in patients with asthma taking inhaled corticosteroids Source: Annual Congress 2011 - Asthma management and response Year: 2011 Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD Source: Eur Respir J 2010; 36: 494-502 Year: 2010 The risk of cardiovascular disease associated with asthma may be mediated by short-acting β2-agonists Source: Annual Congress 2008 - Epidemiology of asthma and allergy Year: 2008 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013